The NIAGRA study used a creatinine clearance threshold of 40 ml/min for cisplatin, lower than the traditional 60 ml/min cutoff. This forward-looking design validates the practice of treating patients with borderline renal function with cisplatin, potentially allowing more individuals with MIBC to benefit from this chemotherapy.

An analysis of EMERALD and LEAP trial criteria against real-world HCC cases reveals that a majority of complex patients (e.g., multifocal, large tumors) who could most benefit from combination therapies were ineligible, cautioning clinicians against broad application of trial results.

Despite logistical challenges like clinic chair time, the ICON 8B study's positive results are forcing a re-evaluation of weekly paclitaxel. The trial demonstrated improved progression-free and overall survival compared to the standard three-week cycle, suggesting a potential shift back to a previously debated dose-dense strategy in the frontline setting.

Clinicians may counsel patients towards therapies with lower efficacy if the dosing schedule is more convenient (e.g., quarterly). The rationale is that a lack of response is evident quickly, allowing a rapid pivot to another treatment without losing significant time or risking progression.

The JCOG 1008 trial defined treatment completion as receiving at least five of seven planned weekly cisplatin doses (200 mg/m²). This provides clinicians with a practical, data-supported minimum target when managing patient toxicity, helping to balance efficacy against the need to push for all seven doses.

While cisplatin is standard in most urothelial cancer settings, carboplatin is an acceptable adjuvant option specifically after nephroureterectomy for upper tract disease. This is a logical adaptation, as patients have lost a kidney, increasing their risk of renal dysfunction with the more nephrotoxic cisplatin.

In the JCOG 1008 trial, the weekly cisplatin arm had better outcomes despite a lower total drug dose. This suggests that maintaining consistent drug levels for radiosensitization throughout radiation is potentially more critical than the overall cumulative dose, which was higher in the less effective three-weekly arm.

The clinical lexicon for recurrent ovarian cancer is evolving. The term "platinum resistant" is being replaced by "platinum ineligible." This reflects a more nuanced clinical judgment that platinum-based chemotherapy is not the best option for a patient's recurrence, rather than being based solely on a time-defined interval of relapse.

The HN009 trial challenged the standard high-dose cisplatin regimen for head and neck cancer. While weekly cisplatin reduced expected hearing and kidney toxicity, it unexpectedly caused more bone marrow toxicity. The overall "toxicity score" showed no difference between arms for HPV-positive patients, halting the trial's progression.